Treatment and rehabilitation of Long COVID: A scope of the literature:Update July 2023

Summary • We identified 18 randomised controlled trials published since early March 2023 that were focused on Long COVID treatment or rehabilitation. Across our five reports produced to date, we have identified and assessed 73 trials published between January 2022 and June 2023. • Over half of the trials in the current update had a primary focus on treating persistent problems with the sense of smell or taste (olfactory/gustatory dysfunction)(n=5) or nonspecific Long COVID symptoms (n=5). Other trials focused on fatigue (n=4); pulmonary/respiratory health (n=1); post COVID lung fibrosis (n=1); musculoskeletal sequelae (n=1); and erectile dysfunction (n=1). • Five trials were rated positively for at least 11 out of the 13 criteria that we assessed. Four trials met 10 criteria and nine gained a positive rating for between five and nine criteria.